The ACS’s mission-driven venture capital fund
Investing in for-profit companies developing novel cancer-focused treatments
Fighting for a world without cancer
Become a Donor
Our vision is to conquer cancer for all communities through patient-centric innovation.
BrightEdge exists to accelerate the American Cancer Society's mission for a world without cancer.
We invest in the development of life-saving therapeutics
BrightEdge invests in the most promising for-profit oncology companies bringing innovative treatments to market.
Fighting for a World Without Cancer
BrightEdge is led by a world-class team of investors, operators, and entrepreneurs to ensure the best cancer innovations are brought to market.
TailorMed Extends Funding Series to $25 Million to Continue Growing its Market-Leading Financial Navigation Platform
Digital financial health company is joined by strategic investors Citi, OSF Ventures, and American Cancer Society’s impact investment fund, BrightEdge.
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic
Immunitas' Series B financing was led by Agent Capital. Funding will be used to advance their novel NK and T cell modulator IMT-009 for the treatment of solid tumor and hematological cancers with an anticipated IND filing in 1H 2022.
See All News